Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Method Developed by VTT Targets Diagnosis of Early Alzheimer’s Disease

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Half of patients could be diagnosed a year earlier than current clinical practice.

A software tool called PredictAD developed by VTT Technical Research Centre of Finland promises to enable earlier diagnosis of the disease on the basis of patient measurements and large databases. Alzheimer’s disease currently takes on average 20 months to diagnose in Europe. VTT has shown that the new method could allow as many as half of patients to get a diagnosis approximately a year earlier.

VTT has been studying whether patients suffering from memory problems could be diagnosed with Alzheimer’s disease at an earlier stage in the light of their measurement values. The study involved processing patient measurements using VTT’s PredictAD system, which was developed to support clinical decision-making. The findings were published in the Journal of Alzheimer’s Disease in November 2012.

VTT has developed a novel approach for measuring the state of the patient reliably and objectively in cooperation with clinicians of University of Eastern Finland and Copenhagen University Hospital Rigshospitalet. The system compares the patient’s measurements with measurements of other patients in large databases and provides an index and a graphical representation reflecting the state of the patient. Modern hospitals have huge data reserves that could be utilised in diagnostics by systematic mathematical modelling. Successful early diagnostics combined with new forms of care may reduce suffering and delay the institutionalisation of patients.

VTT’s decision support system and imaging methods developed by VTT and Imperial College London were studied using ADNI material compiled in the United States. The study covered the records of a total of 288 patients suffering from memory problems, 140 of whom were diagnosed with Alzheimer’s disease on average 21 months after the initial measurements.

The study showed that half of the patients could have been given a diagnosis of Alzheimer’s disease around a year earlier. The accuracy of the predictions was comparable to clinical diagnosis. Treatments designed to slow down the progress of the disease could therefore be started earlier.

Early prediction of the disease is also important from the perspective of drug trials. If patients whose disease is still in the early stages can be included in trials, the treatment can be expected to be more effective.

The method will be tested at several memory clinics in Europe over the next few years. VTT’s goal is to expand the method to also cover several other illnesses that cause dementia in addition to Alzheimer’s disease.

Alzheimer’s disease is the most common cause for dementia. It was estimated that there were 35.6 million people living with dementia worldwide in 2010, and that the number will rise to 65.7 million by 2030. The estimated costs of dementia were 604 billion USD worldwide in 2010. About 70% of the costs are made Western Europe and North America. Dementia accounts for about 1% of the world’s gross domestic product. (Alzheimer’s Disease Int., 2010) http://www.alz.co.uk/research/world-report

Alzheimer’s is the sixth-leading cause of death in the USA, and the only major disease where mortality is still on the rise. http://www.alz.org/alzheimers_disease_facts_and_figures.asp#quickfacts


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VTT Printed a Morphine Test on Paper
Company use antibodies as morphine sensing molecules when creating this morphine test.
Saturday, April 18, 2015
European Research Project Aims at Early Diagnosis of Memory Disorders
800 patients to participate in testing new diagnostic procedures.
Thursday, March 20, 2014
Novel Cancer Cell DNA Damage Repair Mechanism
Findings result from application of the cell microarray screening method developed at VTT.
Monday, December 23, 2013
International Prize for VTT's Allergy Vaccine Development Work
First vaccines to be ready for launch in about five years.
Monday, December 09, 2013
Powerful Enzymes Create Ethanol from Agricultural Harvest Waste
The mainly EU-funded DISCO project coordinated by VTT Technical Research Centre of Finland has developed powerful enzymes, which accelerate plant biomass conversion into sugars and further into products such as bioethanol.
Wednesday, January 09, 2013
Food Industry’s High-Quality Co-Streams Used Effectively as Raw Material for New Products
Researchers develop new ways of using substantial co-streams from fish and oil plant processing.
Tuesday, August 14, 2012
VTT and GE Healthcare Developing Novel Biomarkers to Predict Alzheimer’s Disease
VTT and University of Eastern Finland scientists have discovered a serum biochemical signature.
Wednesday, June 27, 2012
Heparin-like Compounds Inhibit Breast Cancer Metastasis to Bone
Heparin-like compounds decreased bone destruction and tumor growth in bone.
Friday, June 15, 2012
VTT Identified Specific Bacteria which Precede Autoimmune Diabetes
New potential avenues for early disease detection and prevention.
Friday, October 28, 2011
Finnish Twin Study Yields New Information on How Fat Cells Cope With Obesity
The team used lipidomics to study the fat tissue biopsies among several sets of monozygotic twins.
Friday, July 29, 2011
One Step Closer to a Diagnostic Test for Schizophrenia
Scientists in Finland have revealed metabolic abnormalities that are associated with schizophrenia.
Thursday, April 14, 2011
VTT is Searching for New Drug Targets for Prostate Cancer in the New IMI PREDECT Project
PREDECT, one of IMI’s new projects, is developing novel models for breast, prostate and lung cancers.
Monday, April 04, 2011
New Potential Drug Targets Discovered for Preventing Prostate Cancer Cell Growth
Researchers from VTT Technical Research Centre of Finland and the University of Turku have discovered four metabolic enzymes regulating prostate cancer cell growth.
Friday, February 18, 2011
Zora Biosciences Commercializes VTT's Biotechnology Expertise
Zora will provide laboratory services to pharmaceutical industry in the area of metabolomics and associated bioinformatics.
Wednesday, June 27, 2007
VTT Develops Software Tool to Integrate and Analyze Complex Medical Data
The megNet® software can be applied in understanding complex relations in living organisms, and characterizing various diseases, such as cardiac diseases and diabetes.
Friday, April 27, 2007
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!